1994년 3월부터 1996년 9월까지 인하병원 산부인과 갱년기클리닉에 내원한 폐경여성 중 자궁적출술을 시행한 110명을 대상으로 이중 57명은 경구용 에스트로겐 제제(premarin), 53명에게는 경피적 에스트로겐 제제(estraderm TTS 50)을 6개월간 투여한 후 투여직전 및 투여 6개월 후의 혈청지질 및 지단백질치를 측정하였다. 혈청 총 cholesterol치는 경구투여군에서 4.77%, 경피투여군에서 4.46% 감소하였고, HDL cholesterol 은 경구투여군에서 11.1%, 경피투여군에서 7.02% 증가하였으며, LDL cholesterol은 경구투여군에서 14.6%, 경피투여군에서 9.61% 감소하였다. Triglyceride는 두 군 모두 치료 전후 유의한 차이가 없었 다. 각각의 변화는 두 군간에 통계적으로 유의한 차 이가 없었다. 이상의 결과로 폐경후 여성에서 혈청지질 및 지 단백질치에 미치는 에스트로겐의 경구적 및 경피적 투여 방법에는 그 효과의 차이가 없는 것으로 사료 된다.

Estrogen replacement therapy in postmenopausal women has been known to reduce the risk of cardiovascular disease, and this effect is thought to be mediated in part by favorable changes in serum lipids and lipoproteins. The other cardiovascular protective effects of estrog-ens are vasodilation, anticoagulation and an antiatherosclerosis effects on blood vessels. To elucidate the main effects of estrogen on the levels of serum lipids and lipoproteins, we conducted the randomized trials of oral and transdermal estrogens in healthy hysterectomized postmenopausal women. In this study, the first group(57 patients) received Premarin(conjugated estrogen) 0.625 mg per day. And the second group(53 patients) received transdermal estradiol patches(Estraderm TTS 50) twice weekly. Serum total cholesterol, triglyceride, HDL cholesterol, and LDL cholesterol levels in fasting state were measured in all subjects before treatment and 6 months after treatment. In both groups, serum total cholesterol levels and serum LDL cholesterol levels were decreased significantly after 6 months of treatment. Also, serum HDL cholesterol levels were increased significantly after treatment. Serum triglyceride level was increased in group 1 and decreased in group 2, but there were no statistical significances. The degrees of change were not differ significantly in both groups. These data suggests that the postmenopausal use of estrogens in hysterectomized women, administered by either oral or transdermal route favorably alters serum LDL and HDL levels that may protect women against cardiovascular disease and there are no significant differences statistically between two regimens on the serum lipids and lipoprotein levels. Considering the costs, the side effects and the compliance of patients on the estrogen replacement therapy, oral forms of estrogen are thought to be the first line of therapy in hysterectomized postmenopausal women.